Product image of Neisvac-C (N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid) supplied by GNH India

Neisvac-C

Active Ingredient:
N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid
Origin:
EU

Neisvac-C (N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid)

N. meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid, the active ingredient in Neisvac-C, is a vaccine presented as an injectable solution for intramuscular use. It is used to prevent invasive disease caused by Neisseria meningitidis serogroup C in individuals at risk.

GNH India supplies Neisvac-C as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pfizer S.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Neisvac-C is a meningococcal conjugate vaccine indicated for prevention of invasive disease caused by Neisseria meningitidis serogroup C.

  • Infants and toddlers: induction of protective antibodies against serogroup C meningococcal disease.
  • Adolescents and young adults: maintenance of immunity to prevent invasive meningococcal C infection.
  • Adults at increased risk (e.g., travelers, immunocompromised): reduction of incidence of serogroup C invasive disease.

How It Works

  • Neisvac-C contains a de-O-acetylated polysaccharide from Neisseria meningitidis group C chemically linked to tetanus toxoid. The conjugation converts the polysaccharide into a T‑cell‑dependent antigen, prompting robust B‑cell activation and high‑affinity IgG antibody production that neutralizes the meningococcal capsule and prevents bacterial invasion.

Side Effects

Neisvac-C is generally well tolerated, but injection‑site reactions and systemic symptoms may occur.

Common Side Effects

  • Pain at the injection site: mild to moderate discomfort.
  • Redness or swelling: localized inflammatory response.
  • Fever: transient low‑grade temperature rise.
  • Headache: mild to moderate intensity.
  • Fatigue: temporary tiredness.
  • Myalgia: muscle aches near the injection area.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare autoimmune neuropathy.
  • Seizures: uncommon neurologic event.
  • Hypotension: sudden drop in blood pressure.
  • Severe local necrosis: extensive tissue damage at injection site.
  • Thrombotic events: extremely rare clot formation.

Precautions & Warnings

Before administering Neisvac-C, consider the following safety measures.

  • Pregnancy: safety not established; use only if benefits outweigh risks.
  • Breastfeeding: unknown effects; evaluate risk‑benefit ratio.
  • Immunocompromised patients: may mount a reduced immune response.
  • Severe allergy: avoid if known hypersensitivity to any vaccine component.
  • Concomitant vaccines: follow recommended intervals to avoid interference.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Neisvac-C may interact with other agents; monitor as indicated.

Major Interactions (Avoid)

  • Live attenuated vaccines: avoid simultaneous administration to prevent interference.
  • Whole‑blood transfusion: postpone vaccination for at least 4 weeks after transfusion.

Moderate Interactions (Monitor Closely)

  • Immunoglobulin therapy: may diminish vaccine‑induced immunity; schedule vaccination before therapy when possible.
  • Antipyretics (e.g., acetaminophen): can mask fever, monitor for underlying infection.
  • Immunosuppressive drugs: may reduce antibody response; assess need for booster doses.
  • Antibiotics: generally no effect, but monitor for allergic cross‑reactivity if penicillin‑based.

Frequently Asked Questions

Neisvac-C is a conjugate vaccine designed to prevent invasive disease caused by Neisseria meningitidis serogroup C. It stimulates the immune system to produce antibodies that neutralize the bacterial capsule, thereby reducing the risk of meningococcal meningitis and septicemia in individuals at risk.

The active ingredient is a de‑O‑acetylated polysaccharide from meningococcal group C linked to tetanus toxoid. This conjugation creates a T‑cell‑dependent antigen that elicits a strong, long‑lasting IgG antibody response, providing protective immunity against the serogroup C strain.

The dosing regimen for Neisvac-C is determined by the prescribing healthcare professional based on age, risk factors and local immunization schedules. The prescriber will specify the number of doses, interval between doses and any booster requirements.

Safety data for Neisvac-C in pregnancy and lactation are limited. It should only be administered if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To request Neisvac-C, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Neisvac-C is a conjugate vaccine that uses tetanus toxoid as a carrier protein, offering a T‑cell‑dependent response and longer‑lasting immunity compared with plain polysaccharide vaccines. It is comparable to other licensed group C conjugate vaccines but may differ in carrier protein, dosing schedule and regional licensing.

Neisvac-C must be stored in a refrigerated environment at 2 °C to 8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the solution. Do not use the product if the cold chain has been broken.

Neisvac-C is given as a single‑dose intramuscular injection, typically into the deltoid muscle of the upper arm. The injection should be performed by a qualified healthcare professional using aseptic technique and following local immunization guidelines.

The most serious adverse events reported with Neisvac-C include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, and rare neurologic events like seizures. Immediate medical attention is required if any signs of a severe reaction appear after vaccination.

Neisvac-C should not be administered to individuals with a known severe hypersensitivity to any component of the vaccine, including the tetanus toxoid carrier. It is also contraindicated in persons who have experienced a previous severe allergic reaction to a meningococcal conjugate vaccine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT